Immunotherapy in the adjuvant setting for high-risk melanoma.

Immunotherapy in the adjuvant setting for high-risk melanoma. Clin Adv Hematol Oncol. 2018 Aug;16(8):546-548 Authors: Weber JS PMID: 30148825 [PubMed - in process]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research